课题基金 / 基金详情

APOPTOSIS AND %S AS PROGNOSTIC FACTORS FOR COLON CANCER

APOPTOSIS AND %S AS PROGNOSTIC FACTORS FOR COLON CANCER
细胞凋亡%20AND%20%S%20AS%20预后%20因素%20FOR%20结肠%20癌症
批准号:
2691257
负责人:
Thomas E. Witzig
金额:
$14.15万
依托单位:
依托单位国家:
美国
项目类别:
财政年份:
1998
资助国家:
美国
项目状态:
已结题
起止时间:
1998-07-01 至 2000-06-30

项目摘要

项目成果

Thomas E. Witzig的其他基金

相似基金

相关文献

中文摘要
翻译
点击翻译按钮获取中文摘要
英文摘要
The growth of a colon cancer is determined by the rates of malignant cell proliferation and natural apoptosis. Because of molecular genetic changes in the cancer cell both of these processes can be disrupted and lead to tumor growth. We hypothesize that the rate of colon cancer cell apoptosis is an important determinant of net cancer cell growth and that a measure of the percent cells in apoptosis will provide additional prognostic information to the cell proliferation rate. The overall goals of this proposal are to measure the rates of basal apoptosis and cell proliferation on specimens of colon adenocarcinomas and relate these measurements to prognosis and the molecular genetic abnormalities determined on the same tumor sample. Paraffin-embedded tissue from patients that participated in randomized, controlled NCCTG clinical trials which now have adequate follow-up data to correlate these measurements to colon cancer recurrence and survival. Cell proliferation and DNA ploidy will be measured using state-of-the-art flow cytometry hardware and software. Apoptosis will be measured with a TUNEL technique. We propose to utilize the cell proliferation (percent S and percent G2M phases) and percent apoptosis measurements to develop a formula - the colon cancer growth index (CCGI) - that better predicts prognosis. The second hypothesis to be tested is that the alterations of cancer cell proliferation and apoptosis are the consequences of genetic abnormalities and that these genetic abnormalities will differentially affect proliferation and apoptosis. This study offers the unique opportunity to study the cell proliferation and apoptosis rates of colon cancers that have already been studied for molecular abnormalities by Dr. Steven Thibodeau in a previous study (NCCTG 93-46-55). By performing these assays on clinical material, we aim to translate these findings into prognostic tools that can be used in the clinic to formulate new treatment strategies based on the knowledge of apoptosis and cell proliferation of colon cancers.
期刊论文(0)
专著(0)
科研奖励(0)
会议论文
P2 - Signal Transduction Inhibitor Therapy for Lymphoma
  • 批准号:
    8076889
  • 项目类别:
  • 资助金额:
    $29.73万
  • 财政年份:
    2010
  • 负责人:
    Thomas E. Witzig
  • 依托单位:
Signal transduction inhibitor therapy for Lymphoma
  • 批准号:
    8101349
  • 项目类别:
  • 资助金额:
    $32.58万
  • 财政年份:
    2007
  • 负责人:
    Thomas E. Witzig
  • 依托单位:
Signal Transduction Inhibitor Therapy for Lymphoma
  • 批准号:
    7254591
  • 项目类别:
  • 资助金额:
    $32.03万
  • 财政年份:
    2007
  • 负责人:
    Thomas E. Witzig
  • 依托单位:
Signal transduction inhibitor therapy for Lymphoma
  • 批准号:
    7498465
  • 项目类别:
  • 资助金额:
    $33.05万
  • 财政年份:
    2007
  • 负责人:
    Thomas E. Witzig
  • 依托单位:
国内基金
海外基金
Epac1/2通过蛋白酶体调控中性粒细胞NETosis和Apoptosis在急性肺损伤中的作用研究
  • 批准号:
    LBY21H010001
  • 项目类别:
    省市级项目
  • 资助金额:
    --
  • 批准年份:
    2020
  • 负责人:
    郑绪阳
  • 依托单位:
基于Apoptosis/Ferroptosis双重激活效应的天然产物AlbiziabiosideA的抗肿瘤作用机制研究及其结构改造
  • 批准号:
    81703335
  • 项目类别:
    青年科学基金项目
  • 资助金额:
    20.0万元
  • 批准年份:
    2017
  • 负责人:
    卫高菲
  • 依托单位:
双肝移植后Apoptosis和pyroptosis在移植物萎缩差异中的作用和供受者免疫微环境变化研究
  • 批准号:
    81670594
  • 项目类别:
    面上项目
  • 资助金额:
    58.0万元
  • 批准年份:
    2016
  • 负责人:
    陈昊
  • 依托单位:
Serp-2 调控apoptosis和pyroptosis 对肝脏缺血再灌注损伤的保护作用研究
  • 批准号:
    81470791
  • 项目类别:
    面上项目
  • 资助金额:
    73.0万元
  • 批准年份:
    2014
  • 负责人:
    董家鸿
  • 依托单位: